Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation

American Journal of Transplantation

Volumn 14, Issue 2, 2014, Pages 459-465

  Lonze, B E ^a   Zachary, A A ^a   Magro, C M ^b   Desai, N M ^a   Orandi, B J ^a   Dagher, N N ^a   Singer, A L ^a   Carter Monroe, N ^a   Nazarian, S M ^a   Segev, D L ^a   Streiff, M B ^a   Montgomery, R A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibodies; coagulation; complement regulation; kidney transplantation

Indexed keywords

COMPLEMENT INHIBITOR; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; COMPLICATION; FOLLOW UP; GRAFT REJECTION; HUMAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT INACTIVATING AGENTS; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION;

EID: 84895064562     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12540     Document Type: Article

References (30)

1. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA., Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
2. Salmela B, Hartman J, Peltonen S, Alback A, Lassila R., Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol 2013; 8: 962-968.
3. Asherson RA., The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508-512.
4. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.
5. Asherson RA, Espinosa G, Cervera R, Font J, Carles Reverter J., Catastrophic antiphospholipid syndrome: Proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002; 8: 157-165.
6. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195-207.
7. Erkan D, Asherson RA, Espinosa G, et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62: 530-533.
8. Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506-517.
9. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L., Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-1264.
10. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
11. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
12. Magro CM, Poe JC, Kim C, et al. Degos disease: A C5b-9/interferon-alpha- mediated endotheliopathy syndrome. Am J Clin Pathol 2011; 135: 599-610.
13. Lonze BE, Singer AL, Montgomery RA., Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744-1745.
14. Vaidya S, Sellers R, Gugliuzza K, Daller J, Fish JC., Therapy in ESRD patients with antiphospholipid antibody syndrome. Transplant Proc 2001; 33: 1257-1258.
15. Canaud G, Bienaime F, Noel LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010; 10: 2051-2060.
16. Levine JS, Branch DW, Rauch J., The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
17. Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y., The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. J Autoimmun 2009; 32: 1-6.
18. Nester CM, Brophy PD., Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr 2013; 25: 225-231.
19. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997; 150: 2019-2031.
20. Liu L, Qiu W, Wang H, et al. Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1-dependent caspase 8 activation. J Biol Chem 2012; 287: 16410-16423.
21. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-559.
22. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
23. Chapin J, Weksler B, Magro C, Laurence J., Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157: 772-774.
24. Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N., The use of eculizumab in renal transplantation. Clin Transplant 2013; 27: E216-229.
25. Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP., Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: A case report. Transplant Proc 2012; 44: 3037-3040.
26. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
27. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11: 2523-2527.
28. Devreese K, Hoylaerts MF., Laboratory diagnosis of the antiphospholipid syndrome: A plethora of obstacles to overcome. Eur J Haematol 2009; 83: 1-16.
29. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013; 13: 2179-2185.
30. Harris RJ, Cropley TG., Possible role of hypercoagulability in calciphylaxis: Review of the literature. J Am Acad Dermatol 2011; 64: 405-412.